Donald C. Porter

Senex Biotechnology, Inc.

$3,844,914

Attributed

$3,994,910

Total exposure

Grants

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.1M · FY2006–17

$2M$1.5M$1M$500K$0

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

Funding mix

By agency

NIH$3,994,910 · 9

By mechanism

R44$2,541,124 · 2

R43$1,453,786 · 7

Top collaborators

Eugenia V Broude1 shared

Others in their field

Top investigators on “Inhibitor/Antagonist”

John M Lachin · George Washington University$117,867,649
David M Nathan · Massachusetts Institute Of Technology$117,867,649
Randall J Bateman · Washington University$110,978,751
David Heimbrook · Leidos Biomedical Research, Inc.$72,139,282
Keri Hammel · The Emmes Company, Llc$53,700,408
Walter John Curran · Thomas Jefferson University$32,790,605

Research focus

Inhibitor/AntagonistProgramsPharmaceutical PreparationsProteinsSmall Business Innovation Research GrantBaseTumorMalignant NeoplasmsIn VivoLeadToxic EffectCyclin-Dependent Kinase InhibitorPhosphotransferasesFamilyProductionGenesGenetic TranscriptionNeoplastic CellPre-ClinicalBiotechnologyCdk2 GeneCyclin-Dependent KinasesCellsCell Line